160 related articles for article (PubMed ID: 12414343)
1. p53 and mdm2 in mantle cell lymphoma in leukemic phase.
Solenthaler M; Matutes E; Brito-Babapulle V; Morilla R; Catovsky D
Haematologica; 2002 Nov; 87(11):1141-50. PubMed ID: 12414343
[TBL] [Abstract][Full Text] [Related]
2. CDK4 and MDM2 gene alterations mainly occur in highly proliferative and aggressive mantle cell lymphomas with wild-type INK4a/ARF locus.
Hernández L; Beà S; Pinyol M; Ott G; Katzenberger T; Rosenwald A; Bosch F; López-Guillermo A; Delabie J; Colomer D; Montserrat E; Campo E
Cancer Res; 2005 Mar; 65(6):2199-206. PubMed ID: 15781632
[TBL] [Abstract][Full Text] [Related]
3. Expression of Mcl-1 in mantle cell lymphoma is associated with high-grade morphology, a high proliferative state, and p53 overexpression.
Khoury JD; Medeiros LJ; Rassidakis GZ; McDonnell TJ; Abruzzo LV; Lai R
J Pathol; 2003 Jan; 199(1):90-7. PubMed ID: 12474231
[TBL] [Abstract][Full Text] [Related]
4. mdm-2 oncoprotein expression associated with deletion of the long arm of chromosome 12 in a case of mantle cell lymphoma with blastoid transformation [corrected].
Haidar JH; Neiman RS; Orazi A; Albitar M; McCarthy LJ; Heerema N
Mod Pathol; 1996 Apr; 9(4):355-9. PubMed ID: 8729971
[TBL] [Abstract][Full Text] [Related]
5. MYC overexpression correlates with MYC amplification or translocation, and is associated with poor prognosis in mantle cell lymphoma.
Choe JY; Yun JY; Na HY; Huh J; Shin SJ; Kim HJ; Paik JH; Kim YA; Nam SJ; Jeon YK; Park G; Kim JE
Histopathology; 2016 Feb; 68(3):442-9. PubMed ID: 26100211
[TBL] [Abstract][Full Text] [Related]
6. Altered expression of p53 and MDM2 proteins in hematological malignancies.
Koníková E; Kusenda J
Neoplasma; 2003; 50(1):31-40. PubMed ID: 12687276
[TBL] [Abstract][Full Text] [Related]
7. Gene abnormalities in multiple myeloma; the relevance of TP53, MDM2, and CDKN2A.
Elnenaei MO; Gruszka-Westwood AM; A'Hernt R; Matutes E; Sirohi B; Powles R; Catovsky D
Haematologica; 2003 May; 88(5):529-37. PubMed ID: 12745272
[TBL] [Abstract][Full Text] [Related]
8. Oncoprotein MDM2 overexpression is associated with poor prognosis in distinct non-Hodgkin's lymphoma entities.
Møller MB; Nielsen O; Pedersen NT
Mod Pathol; 1999 Nov; 12(11):1010-6. PubMed ID: 10574597
[TBL] [Abstract][Full Text] [Related]
9. Alterations affecting the p53 control pathway in bilharzial-related bladder cancer.
Osman I; Scher HI; Zhang ZF; Pellicer I; Hamza R; Eissa S; Khaled H; Cordon-Cardo C
Clin Cancer Res; 1997 Apr; 3(4):531-6. PubMed ID: 9815716
[TBL] [Abstract][Full Text] [Related]
10. [Expression of P21 WAF1/CIP1 in human astrocytomas in correlating with P53, MDM2, and cellular proliferation index].
Xu QZ; Liu F; Lu DH; Yu SZ; Yang H
Zhongguo Yi Xue Ke Xue Yuan Xue Bao; 2001 Aug; 23(4):341-5. PubMed ID: 12940073
[TBL] [Abstract][Full Text] [Related]
11. TCL1 expression predicts overall survival in patients with mantle cell lymphoma.
Shin SJ; Roh J; Cha HJ; Choi YD; Kim JM; Min SK; Kim JE; Eom DW; Lee H; Kim HJ; Yoon DH; Suh C; Huh J
Eur J Haematol; 2015 Dec; 95(6):583-94. PubMed ID: 25688912
[TBL] [Abstract][Full Text] [Related]
12. [Study on MDM2 and p53 gene proteins expression on acute leukemic cells and its correlation with chemotherapeutic efficacy].
Lin M; Liu Y; Jin J
Zhonghua Xue Ye Xue Za Zhi; 1998 Jul; 19(7):350-2. PubMed ID: 11189516
[TBL] [Abstract][Full Text] [Related]
13. Strong correlation of basement membrane degradation with p53 inactivation and/or MDM2 overexpression in superficial urothelial carcinomas.
Ozdemir E; Kakehi Y; Okuno H; Habuchi T; Okada Y; Yoshida O
J Urol; 1997 Jul; 158(1):206-11. PubMed ID: 9186361
[TBL] [Abstract][Full Text] [Related]
14. mdm2 expression as a prognostic indicator in clear cell renal cell carcinoma: comparison with p53 overexpression and clinicopathological parameters.
Haitel A; Wiener HG; Baethge U; Marberger M; Susani M
Clin Cancer Res; 2000 May; 6(5):1840-4. PubMed ID: 10815906
[TBL] [Abstract][Full Text] [Related]
15. Stabilization and activation of p53 downregulates mTOR signaling through AMPK in mantle cell lymphoma.
Drakos E; Atsaves V; Li J; Leventaki V; Andreeff M; Medeiros LJ; Rassidakis GZ
Leukemia; 2009 Apr; 23(4):784-90. PubMed ID: 19225536
[TBL] [Abstract][Full Text] [Related]
16. MDM2 and p53 protein expression in the histologic subtypes of endometrial carcinoma.
Ambros RA; Sheehan CE; Kallakury BV; Ross JS; Malfetano J; Paunovich E; Figge J
Mod Pathol; 1996 Dec; 9(12):1165-9. PubMed ID: 8972476
[TBL] [Abstract][Full Text] [Related]
17. Loss of the p53 tumor suppressor activity is associated with negative prognosis of mantle cell lymphoma.
Stefancikova L; Moulis M; Fabian P; Ravcukova B; Vasova I; Muzik J; Malcikova J; Falkova I; Slovackova J; Smardova J
Int J Oncol; 2010 Mar; 36(3):699-706. PubMed ID: 20126990
[TBL] [Abstract][Full Text] [Related]
18. Blastoid and common variants of mantle cell lymphoma exhibit distinct immunophenotypic and interphase FISH features.
Parrens M; Belaud-Rotureau MA; Fitoussi O; Carerre N; Bouabdallah K; Marit G; Dubus P; de Mascarel A; Merlio JP
Histopathology; 2006 Mar; 48(4):353-62. PubMed ID: 16487357
[TBL] [Abstract][Full Text] [Related]
19. Abnormalities of the P53, MDM2, BCL2 and BAX genes in acute leukemias.
Wojcik I; Szybka M; Golanska E; Rieske P; Blonski JZ; Robak T; Bartkowiak J
Neoplasma; 2005; 52(4):318-24. PubMed ID: 16059649
[TBL] [Abstract][Full Text] [Related]
20. Aggressive morphologic variants of mantle cell lymphoma characterized with high genomic instability showing frequent chromothripsis, CDKN2A/B loss, and TP53 mutations: A multi-institutional study.
Streich L; Sukhanova M; Lu X; Chen YH; Venkataraman G; Mathews S; Zhang S; Kelemen K; Segal J; Gao J; Gordon L; Chen Q; Behdad A
Genes Chromosomes Cancer; 2020 Aug; 59(8):484-494. PubMed ID: 32277542
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]